Systemic therapy in metastatic renal cell carcinoma
暂无分享,去创建一个
H. Tesch | T. Gauler | K. Miller | V. Grünwald | S. Zastrow | J. Bedke | M. Schostak | S. Schmitz | S. Hinz | E. Herrmann | A. Hegele | J. Janssen
[1] P. Kantoff,et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[2] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[3] M. Staehler,et al. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. , 2015, European urology.
[4] B. Rini,et al. 17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC , 2015 .
[5] R. Motzer,et al. 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) , 2015 .
[6] R. Motzer,et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). , 2015 .
[7] A. Stenzl,et al. Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma , 2015, Human vaccines & immunotherapeutics.
[8] T. Choueiri,et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. , 2015, The Lancet. Oncology.
[9] P. Karakiewicz,et al. Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence , 2014, International journal of nephrology and renovascular disease.
[10] Tae Min Kim,et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Porta,et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[12] M. Staehler,et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). , 2014 .
[13] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[14] T. Choueiri,et al. Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria , 2013, Cancer.
[15] The Cancer Genome Atlas Research Network. COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.
[16] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[17] R. Motzer,et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[18] S. Shariat,et al. The changing face of renal cell carcinoma: the impact of systematic genetic sequencing on our understanding of this tumor's biology. , 2013, European urology.
[19] Lauren McCann,et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.
[20] S. Stevanović,et al. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy , 2013, World Journal of Urology.
[21] J. Dutcher,et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis , 2013, British Journal of Cancer.
[22] C. Porta,et al. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. , 2012, European journal of cancer.
[23] R. Motzer,et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.
[24] M. Rosenblum,et al. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel–Lindau gene and hypoxia-inducible factor pathway-related proteins , 2011, Modern Pathology.
[25] Lorenzo Marconi,et al. EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.
[26] Norbert Hollaender,et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.
[27] A. Ravaud,et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Sternberg,et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Xin Huang,et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Mclaughlin,et al. Epidemiologic characteristics and risk factors for renal cell cancer , 2009, Clinical epidemiology.
[31] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[32] Bohuslav Melichar,et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.
[33] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[34] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[35] R. Motzer,et al. Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma , 2006, Clinical Cancer Research.
[36] N. Rioux-Leclercq,et al. Understanding the importance of smart drugs in renal cell carcinoma. , 2006, European urology.
[37] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[38] M. Kattan,et al. A postoperative prognostic nomogram for renal cell carcinoma. , 2001, The Journal of urology.
[39] K. Bensalah,et al. Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. , 2016, European urology.
[40] J. Himmelfarb,et al. Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib , 2014 .
[41] M. Karno,et al. Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.